Pediococcus acidilactici CCFM6432 alleviates anhedonia in major depression through immune-inflammatory modulation: An extended trial analysis

doi:10.5498/wjp.v16.i3.114446

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (25)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-1)

Sum=27

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=50

Publishing Process of This Article

Item

Count

Browse

Download

Sum=1

Mar 19, 2026 (publication date) through Feb 28, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.

World J Psychiatry. Mar 19, 2026; 16(3): 114446
Published online Mar 19, 2026. doi: 10.5498/wjp.v16.i3.114446

Pediococcus acidilactici CCFM6432 alleviates anhedonia in major depression through immune-inflammatory modulation: An extended trial analysis

Du-Xing Li, Yi Gu, Wen-Juan Xia, Yi-Fan Sun, Lu Hou, Wen-Xian Zhu, Jun Wang

Du-Xing Li, Yi Gu, Wen-Juan Xia, Yi-Fan Sun, Wen-Xian Zhu, Jun Wang, Department of Psychiatry, The Affiliated Mental Health Center of Jiangnan University, Wuxi 214151, Jiangsu Province, China

Lu Hou, Department of Psychiatry, Huai’an Third People’s Hospital, Huai’an 223001, Jiangsu Province, China

Author contributions: Li DX, Xia WJ, and Wang J contributed to conceptualization; Li DX and Gu Y contributed to formal analysis; Gu Y, Sun YF, and Hou L contributed to software; Xia WJ, Hou L, and Zhu WX contributed to investigation; Xia WJ and Wang J contributed to writing - review and editing; Sun YF, Zhu WX, and Wang J contributed to resources; Li DX contributed to methodology, visualization, writing - original draft; Gu Y contributed to data curation; Zhu WX contributed to supervision; Wang J contributed to funding acquisition.

Supported by the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee, No. BJ2023086; and Wuxi Taihu Talent Project, No. WXTTP 2021.

Institutional review board statement: This study received approval from the Ethics Committee of Wuxi Mental Health Center (No. WXMHCIRB2023 LLky030) and adhered rigorously to the principles of the Declaration of Helsinki.

Clinical trial registration statement: This study was retrospectively registered at https://www.chictr.org.cn/ (registration number: No. ChiCTR2400093687; date of registration: December 10, 2024).

Informed consent statement: Informed consent was obtained from all subjects involved in the study.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.

Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Corresponding author: Jun Wang, MD, PhD, Department of Psychiatry, The Affiliated Mental Health Center of Jiangnan University, No. 156 Qianrong Road, Binhu District, Wuxi 214151, Jiangsu Province, China. woodfish2@126.com

Received: September 19, 2025
Revised: November 6, 2025
Accepted: December 9, 2025
Published online: March 19, 2026
Processing time: 162 Days and 16.8 Hours

Core Tip

Core Tip: This study investigated whether Pediococcus acidilactici CCFM6432 alleviates anhedonia in major depressive disorder through immune-inflammatory modulation and reward-related electrophysiological changes. The probiotic significantly reduced inflammatory markers (lipopolysaccharide, C-reactive protein, and interleukin-6) and enhanced reward anticipation, as reflected by increased stimulus-preceding negativity amplitude and higher Temporal Experience of Pleasure Scale scores. These results suggest that CCFM6432 may improve anhedonia via an immune-inflammatory pathway. Large-scale, multicenter studies integrating multimodal biomarkers are warranted to validate and extend these findings.